Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16457244 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16457243 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1033852 | 0.84 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL1666348 | 0.84 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL2369966 | 0.83 | SLC5A2 (0.51) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16473307 | 0.83 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1036645 | 0.80 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1037836 | 0.80 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14188980 | 0.80 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2997996 | 0.80 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9365602-B2 | Sodium glucose co-transporter inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365602-B2 | Sodium glucose co-transporter inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-05-15 | — | — | US | disclosed |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-05-15 | — | — | US | disclosed |
| EP-2308841-B1 | Phlorizin analogs as SGLT2 inhibitors | LEXICON PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2308841-B1 | Phlorizin analogs as SGLT2 inhibitors | LEXICON PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2008109591-A1 | PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109591-A1 | PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
| WO-2008042688-A2 | PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 | LEXICON PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042688-A2 | PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 | LEXICON PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | SLC2A1, SLC2A2, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885ADRA2A 831/4885 |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SLC5A2 3/4885SLC5A1 5/4885ADRA2A 1393/4885 |
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SLC5A2 3/4885SLC5A1 5/4885ADRA2A 1393/4885 |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SLC5A2 3/4885SLC5A1 5/4885ADRA2A 1393/4885 |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | SLC2A1, SLC2A2, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885ADRA2A 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.